Plain-English translation of NCT06165510 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new two-stage treatment approach for persistent atrial fibrillation — a common heart rhythm problem that doesn't respond well to standard treatments. The new approach combines minimally invasive surgery to ablate (scar) the back of the heart chamber with a device procedure to close off a small pouch in the heart, followed by a second catheter procedure to finish the treatment. The goal is to see if this combination approach works better and lasts longer than the standard catheter-only treatment that doctors use today.
Current standard treatments for persistent atrial fibrillation only work about 40 to 70 percent of the time and often don't last. This trial exists because doctors want to find better options that could reduce patients' need for heart medications, improve quality of life, and prevent repeat hospitalizations.
You likely qualify if…
You likely don't qualify if…
If you are randomly assigned to the new treatment group, you would undergo a two-stage procedure: first, a minimally invasive surgical procedure where doctors access the outside of your heart and seal off a small pouch, then a second catheter-based procedure to confirm and complete the ablation. If assigned to the standard group, you would receive the standard catheter ablation treatment. The study is small (48 patients total) and will track your safety, how well the treatment works, and whether it improves your symptoms over time.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
United Kingdom